Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research
David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.
Dr. O'Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer
March 10th 2020David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.